PMV Pharma gets a whopping $74M round to test a new p53 drug in humans
Mutant p53 proteins have been one of the biggest — and most frustrating — targets in biotech. But an upstart in Cranbury, NJ has landed a whopping $74 million B round to put its approach to the test.
PMV Pharma is following a theory that’s been focused on before. If mutant p53 is the culprit, then restoring the protein and eliminating the mutant escape mechanisms that have kept this target out of reach could prove the key to coming up with an effective therapy. If they’re right, they can go after a pathway involved in roughly half of all tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
